Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Screening Donated Blood for Zika Not Cost-Effective

Universal mini-pool nucleic acid testing only during high mosquito activity cost-effective in Puerto Rico

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Jan. 7, 2019 (HealthDay News) -- Screening donated blood for Zika virus is cost-effective only in the high mosquito season in Puerto Rico, according to a study published online Jan. 8 in the Annals of Internal Medicine.

W. Alton Russell, from Stanford University in California, and colleagues examined the cost-effectiveness of universal individual donation nucleic acid testing (ID-NAT) of donated blood for Zika virus in the first year of screening versus alternatives in a microsimulation that captured Zika-related harms to transfusion recipients, sexual partners, and their infants.

The researchers found that universal mini-pool NAT (MP-NAT) exclusively used during high mosquito season was cost-effective in Puerto Rico at $81,123 per quality-adjusted life-year (QALY). In the 50 states, no screening policy was cost-effective. Compared with no screening, universal ID-NAT cost $341 million per QALY. In the sensitivity analysis, in 64 percent of probabilistic sensitivity analysis iterations, MP-NAT only during the season of high mosquito activity was most cost-effective in Puerto Rico only. No intervention was cost-effective in 99.99 percent of iterations in the 50 states. Cost-effectiveness was highly dependent on the assumed infectious donations rate.

"Current screening policies are extraordinarily costly per QALY saved, which suggests the need for a new paradigm in preventing transfusion-transmitted infections," write the authors of an accompanying editorial.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Last Updated: